Repetitive transcranial magnetic stimulation (rTMS) is an FDA-cleared treatment for depression and obsessive compulsive disorder (OCD) that uses focused magnetic field pulses to stimulate target brain areas. Multiple brain targets in the prefrontal cortex have shown consistent evidence of treatment efficacy in both depression and OCD, but there are currently no established methods for selecting the optimal target site in individual patients.
Additionally, rTMS may underperform or even fail if the rTMS regimen is under-dosed. Delivering an adequate dose of stimulation can be especially challenging during the COVID-19 pandemic, because standard protocols require patients to visit a clinical TMS suite daily for brief sessions for up to 42 days, which poses numerous logistical challenges during the pandemic.
In this open-label study, we will test a new 5-day accelerated rTMS protocol with established efficacy in two recent publications. Subjects will complete a 5-day course of rTMS delivered hourly for 10 hours per day. Subjects who show a partial response to treatment but not a full response will then receive a second 5-day course. The goals of the study are to determine the overall efficacy and trajectory of response to accelerated rTMS for depression or OCD in an open-label context and to identify predictors of differential response to each treatment.
The Weill Cornell Institute of Geriatric Psychiatry is conducting a research study on how brain processes affect emotion regulation, social functioning, and well-being in adults ages 45-70 years old. This study is voluntary and will not influence your regular medical care.
Eligible individuals who agree to participate will take part in:
• An initial screening interview
• Clinical interviews
• Cognitive assessments
• Self-report questionnaires
• One MRI scan
Participants will not be charged for any services. Participants will be compensated up to $300 by the end of the study. All information is confidential. To learn more, please call the study contact.
This is a study to evaluate the effects of perampanel, an FDA-approved drug for epilepsy, on commonly performed neurophysiology tests: electroencephalogram (EEG), somatosensory evoked potential (SEP), brainstem auditory evoked potential (BAEP), and visual evoked potential (VEP). Many other drugs used in the treatment of epilepsy have been shown to affect the results of these tests, but no one has yet examined if perampanel affects these tests.
The investigators plan to recruit 12 healthy normal male subjects. All subjects will have VEP, SEP, EEG, and BAEP performed before and 1 hour after receiving 6mg of oral perampanel. Subjects will also receive a blood draw 1 hour after ingestion of perampanel.
In a previous study done at another institution, healthy volunteers have tolerated a single dose of perampanel at 6 mg quite well. There is no placebo nor randomization. Subject's participation concludes after completion of post-perampanel ingestion neurophysiology tests.
The primary objective of this study is to investigate the efficacy of AKL-T01, a remotely-delivered digital cognitive intervention, relative to a waitlist control in improving cognitive functioning in COVID-19 survivors.
Emerging evidence suggests a subgroup of survivors of COVID- 19 have residual difficulties with cognition and daily functioning. These deficits are pronounced in cognitive domains including attention, learning and executive skills, and may continue to impact quality of life after recovery from other COVID-19 symptoms. This study aims to investigate the efficacy of AKL-T01 (Akili Interactive), a remotely-delivered digital cognitive intervention, in targeting and improving cognition and functional outcomes in individuals recovering from COVID-19. The efficacy of the AKL-T01 intervention will be measured relative to a waitlist control group.
We have developed and validated a non-invasive method to estimate the clearance of cerebrospinal fluid (CSF) from the brain. This study tests the hypothesis that reduced CSF clearance is predictive of a) future amyloid lesions, b) brain atrophy, and c) cognitive decline in healthy elderly adults or those with Mild Cognitive Impairment (MCI).
Measuring brain CSF clearance with novel, experimental imaging techniques may advance the understanding of Alzheimer’s disease (AD) progression at its earliest stages.
All subjects will be enrolled at Weill Cornell Medicine. Study participation consists of 3-5 visits, lasts approximately two years and involves: 1) medical assessment with neurologist, 2) surveys assessing subjective health and well-being, 3) cognitive testing, 4) brain MRI, 5) amyloid PET-CT (FDA approved), 6) tau PET-CT, routine blood & urine analyses, donation of blood for research purposes. The visits occur using telehealth technology, and 3-5 in-person at the Weill Cornell Medicine Clinical and Translational Science Center (CTSC) and the Citigroup Biomedical Imaging Center (CBIC).
The purpose of this study is to investigate differences in iron in the brains of subjects with and without beta-amyloid deposition. Iron is an essential mineral in your body, and beta-amyloid is a protein associated with Alzheimer’s disease. Studies suggest that excess iron in the brain may be involved in processes that lead to Alzheimer's disease. This study will use MRI scans, blood samples, and fluid samples to analyze the relationship between brain iron and proteins related to Alzheimer's disease. Eligible participants will be compensated up to $550 for completing 3 baseline procedures and up to $1100 for participating in the entire study. Additional details will be discussed with the study team.
This is a study to see how effective oral naltrexone is as treatment for prolonged grief disorder (PGD). Participants will take their assigned medication for 8 weeks, with monthly visits to assess symptom severity, social connectedness, and adverse reactions.
The purpose of the IRONMAN study is to establish a noninvasive accurate imaging method for measuring and quantifying iron changes in the brain of subjects with Parkinson’s disease or REM Sleep Behavior Disorder. We will evaluate the rate of iron accumulation throughout different stages of Parkinson’s Disease and compare it to REM Sleep Behavior Disorder patients and healthy volunteers, over a period of 24 months. Thus, we will be able to see if iron starts to accumulate in those patients, long before motor symptoms of Parkinson disease develop. Hypothetically, an iron chelator drug could remove excessive iron from the brain and slow down process of neurodegeneration. A precise technique to measure iron in the brain and to detect small changes therefore is needed as a radiological marker of disease progression and/or therapeutic effect in clinical trials.
Subjects will receive $100 for the first PET scan, $100 for the second PET scan, and $25 for the second MRI. Subjects who are eligible and complete all research visits will receive a total of $225 over the course of the two years of enrollment. We also can reimburse for travel expenses to the study site.
Abnormalities in the Positive Valence System (PVS) are associated with depressive symptoms and reduced behavioral activation in mid- and late-life. This study will investigate the engagement of the PVS during exposure to social rewards, part of a novel streamlined psychotherapy for mid- and late-life depression. Use of computational modeling will enable identification of neuroimaging and behavioral profiles associated with greater treatment response, and may guide future personalization of psychotherapy.
This study will use task-based fMRI and computational modeling to examine how age and late-life depressive symptomatology influence neural network functions and resulting reward and salience processes. This is an observational study that aims to characterize abnormalities in the reward system and salience network at a single timepoint in older adults diagnosed with major depressive disorder and psychiatrically normal controls.
Eligible participants will first complete an assessment session, during which clinical and self- report scales will be administered. Within two business days of the assessment session, participants will complete an MRI scan. We will investigate the association between fMRI activation, behavioral performance, and assessment scores.
The purpose of this study is to measure cerebrospinal fluid (CSF) clearance in subjects with and without high blood pressure. CSF cushions the brain from impact and carries waste products from the brain to the bloodstream. This process is known as clearance.
Researchers have considered that impaired clearance of amyloid (a protein) from the aging brain causes buildup of amyloid in the brain and plays a role in increased risk for Alzheimer’s disease. It is also suspected that clearance may be related to the health of vessels carrying the blood throughout the brain. It is known that high blood pressure damages blood vessels and thus may impair clearance.
In this project we will examine if having high blood pressure is related to impaired brain clearance and whether treating high blood pressure improves clearance and reduces buildup of Alzheimer’s disease-related proteins. This study will examine CSF clearance using positron emission tomography (PET) scanning, which creates images of structures in the body and their functioning. This study will also measure the amount of tau in the brain. Tau and amyloid are proteins that build up in the brains of people with Alzheimer’s disease.
An investigational compound (tracer) called [18F]MK-6240 is injected into the blood prior to the scan in order to take images of the CSF clearance and measure tau protein in the brain. This tracer is considered investigational because it is not approved by the US Food and Drug Administration (FDA) for clinical use and is only being used for research purposes.
In addition to the assessment of tau amount in the brain with PET study described above, the buildup of Alzheimer’s disease-related proteins will also be examined by directly measuring amyloid and tau in the cerebrospinal fluid. To accomplish this goal we will perform lumbar puncture, also known as a spinal tap.
Despite high prevalence of PTSD among LGBT individuals, there are no data characterizing the disorder in this population, nor its treatment. This represents an important under-researched area in LGBT care and treatment. The purpose of this study is: (a) to preliminarily characterize PTSD within an LGBT sample; and (b) to test out the preliminary effects and acceptability of a novel PTSD psychotherapy, trauma-focused psychodynamic psychotherapy, in this group.
Participants identifying as LGBT and meeting DSM-5 criteria for PTSD per a structured, reliable clinical interview for PTSD will receive 20-24 sessions of twice-weekly trauma-focused psychodynamic psychotherapy (TFPP), an experimental intervention, at no cost. Participants will receive four detailed clinical research assessments, at baseline/study entry, Week 5 of treatment, treatment termination/end (Week 12), and 3-months after the end of treatment.
The psychotherapy and assessments in this study have been approved to be performed remotely using teletherapy platforms during the COVID-19 public health crisis.
TFPP is adapted from the only empirically supported, non-exposure focused psychodynamic therapy for panic disorder and anxiety disorders, panic-focused psychodynamic psychotherapy. TFPP aims to improve patients' ability to understand and manage strong, intense emotions that appear seemingly "out of the blue," which links to their tendency to reexperience traumatic events in the here-and-now. TFPP addresses the psychological meanings of symptoms and their relationship to traumatic events to help the patient understand underlying emotions triggering their symptoms and the ways in which trauma influences their current experiences. TFPP was developed for patients with complex PTSD, who often have multiple prior trauma exposures with no clear "index" trauma. Moreover, TFPP also explicitly considers opportunities for patients to explore the broader context of their symptoms and difficulties, including but not limited to LGBT identity or experiences of oppression.
The purpose of this study is to create a registry of volunteers interested in participating in COVID-19 vaccine research. This registry will only be used by researchers at Weill Cornell Medicine (WCM) to identify persons that could be eligible to participate in what we hope will be multiple clinical trials of various COVID-19 vaccines. By entering the registry, you may be able help us understand if certain vaccines can prevent infections with the virus that causes COVID-19.
We anticipate a tremendous amount of interest so we cannot promise to contact all who are interested. We ask that you please complete only one questionnaire per person.
Please understand that your participation in this screening registry is entirely voluntary and you can elect to withdraw from the registry at any time. You may not benefit from participating in this registry. This registry will remain open until the study team has finished recruiting volunteers into the last COVID-19 prevention study which potentially may occur several years from now.
You may be withdrawn from the registry by study staff you enroll in a COVID-19 prevention study, if you do not meet criteria for any of the related studies, or for administrative reasons. This can occur without your consent.
For those interested in joining the study, please visit our registry at: COVID-19 Prevention Network (CoVPN) Screening Registry.
The purpose of this study is to better identify and predict individuals at risk for Alzheimer's disease (AD) who are most likely to benefit from personalized, evidence-based interventions. Studies have shown that endocrine aging (menopause, perimenopause) increases Alzheimer’s disease risk specifically in women. Our goal is to unravel the biological mechanisms behind the increased risk by analyzing how various measures of brain function, biochemistry, laboratory values, and other risk factors may influence Alzheimer’s risk as women age. The ultimate goal of this research is to help characterize the optimal window of opportunity for therapeutic intervention in women at risk for Alzheimer’s.
The mission for this project is to investigate whether the perimenopause to menopause transition, a neuroendocrine transition state specific to the female, drives Alzheimer’s disease (AD) endophenotype in women, thereby playing a determinant role in the well-established increased prevalence of AD in women. As late-onset AD accounts for the greatest incidence and prevalence of the disease, determining sex-specific molecular mechanisms relevant to AD onset and progression has the potential for greatest impact. Further, examination of early stage transitions of risk has the greatest potential for identification of therapeutic targets to change the trajectory of the disease to prevent, delay and potentially reverse course of developing AD.
Translational studies point to the decline in brain 17beta-estradiol as a female-specific trigger for AD. The goal of this study is to examine 16α-[18F]fluoro-17β-estradiol (FES), a selective estrogen receptor (ER) ligand with binding affinity equal to 80% of that of estradiol, for assessment of brain ER activity in humans. Our goals are to leverage our active grants to perform FES-PET in 50 clinically and cognitively normal female participants, aged 40-65 years at different endocrine transition stages. Brain ER status in these groups will be compared to brain biomarkers of AD, e.g. Aβ deposition of PiB-PET, glucose metabolism on FDG-PET, and atrophy on MRI, as well as cognitive performance.
Outcomes of our analyses will elucidate molecular mechanisms that emerge in midlife and that increase risk of developing AD later in life. Collectively, these data will provide therapeutic targets for sex-based precision medicine interventions during the prodromal phase of late-onset AD, when the potential to reverse, prevent and delay AD progression is greatest.
This study seeks to understand how the COVID-19 pandemic is affecting reproductive choices and access to reproductive health care for women ages 18 to 45 who are living in the United States (US).
Please consider taking this brief, anonymous COVID-19 Repro Survey to share your experiences. Your participation will help physicians to learn how best to provide reproductive care to women in times of widespread crisis.
Your answers will be anonymous. No IP addresses or any other information that could be used to identify you will be collected.
This survey was conceived and developed by Susan Loeb-Zeitlin, MD and Margaret Polaneczky, MD at Weill Cornell Medicine. It is not intended to provide medical care or advice. If you have concerns about your personal health, please contact your health care provider.
Thank you for taking the time to add your voice to this research initiative.
This behavioral study will examine how different self-report and clinical rating scales correlate with motivation processes in middle-aged and older adults with depression. The goal is to identify simple measures for characterizing abnormalities in motivation in depressed patients that can be used in the community. Administration of these measures at the outset and during treatment will allow community clinicians to optimize the selection and timing of behavioral interventions.
This study is testing a new mobile app meant for treating anxiety in young adults.
This study involves downloading and using an iPhone app and receiving text messages. You’d be asked to use the app at least twice a week for 20-30 minutes each time. This study involves weekly assessments of your mood and anxiety while you use the app, and one follow-up assessment six weeks later. Participants are compensated $50 each for the baseline, midpoint, endpoint, and follow-up assessments, for a total of $200. There is also an option to complete two MRI scans at Weill Cornell Medicine, before and after using the app program, for an additional $200.
The app is based on cognitive behavioral therapy, an evidence-based treatment for anxiety. Interacting with the app involves watching videos about anxiety, practicing exercises to target challenging thoughts and behaviors, and using relaxation and coping techniques.
This study aims to develop and validate data-driven computational models of the temporal coordination and production of NVC behaviors during dyadic social interactions in TD, ASD, and DD children. We also aim to identify the fine-grained properties of coordination of motor movement and NVC captured by computational models that are most predictive of diagnostic group and one-year language outcomes. Finally, we will explore novel NVC coordination patterns via bottom-up clustering of motor
This study has the goal of furthering our understanding of the longitudinal course of autism spectrum disorder (ASD). Specifically, we propose a longitudinal study of young children with ASD (2-3 years) to identify the neurobiological underpinnings of early developmental changes in restricted repetitive behavior/interests (RRB), one of the most clinically impairing aspects of ASD - and their predictive contribution to later function.
This 9-session behavioral intervention was developed to address the need of primary care interventions for people experiencing chronic pain and depression, which co-exist in late and mid-life, contributing to increased disability, high health care costs, psychiatric comorbidities, and suicide. Participants will have clinically significant depression and suffer from chronic pain and receive either 9 weeks of RELIEF therapy or Usual Care. Research assessments will be conducted at entry, and at 6, 9, and 12 weeks.
The purpose of the study is to help older adults engage in physical exercise and also to help social engagement (opportunities to meet new people). We want to determine whether the Fittle Silver application (app) is effective in engaging older adults in physical activity and increasing social support. The Fittle Silver app is placed on a computer tablet. You are being asked to take part in this study because you are an adult over the age of 60, and are not currently engaged in a physical exercise program or in regular physical exercise activities.
This pilot study examines the interaction of reward and salience abnormalities in depression with the goal to inform a simple-to-administer, structured assessment that will sharpen the targeting of behavioral interventions.
This pilot studies the interplay of reward expectancy and salience functions in mid- and late-life depression. Focusing on three levels of analysis (neural circuitry, performance of PVS-related tasks, self-report/clinical observations) will offer a view of the relationship of neural activation with clinical symptoms.
This study has the goal of furthering our understanding of measuring changes in the presentation of Autism Spectrum Disorder (ASD) symptoms over the lifetime. Specifically, we will measure subtle changes in core symptoms of ASD, including social skills and repetitive and restricted behaviors/interests through the Brief Observation of Social Communication Change (BOSCC). While other diagnostic tests (e.g. ADOS-2, ADI-R) measure these clinical symptoms, they are less sensitive to subtle changes across time that may be a result of intervention, therapy, or other developmental changes. The study will collect short video observations across age (6 months through adults, lifespan), setting (i.e. clinic, home), activity, and social partner (i.e. clinician, parent), in people with ASD, in addition to a typically developing sample at two time points (3-6 months apart, depending on the length of treatment).
The purpose of this study is to evaluate physical reactions associated with PTSD that develops due to the experience of military sexual trauma.
This study aims to compare the effects of 15 sessions (12 weekly in first 12 weeks and 3 monthly booster sessions afterwards) of PATH-MCI (Problem Adaptation Therapy for Mild Cognitive Impairment) vs. ST-CI (Supportive Therapy for Cognitively Impaired Older Adults). Participants receive either 15 weeks of PATH-MCI or Supportive Therapy. Research assessments will be conducted at entry into the study, 6, 12, 24, 36, and 52 weeks.
Anxiety disorders are the most common mental health diagnosis in the US and are associated with avoidance that causes functional impairments and decreases quality of life. Social anxiety disorder is among the most prevalent anxiety disorders, with most common age of onset being in adolescence. The frontline treatment for social anxiety disorder is cognitive behavioral therapy with exposure. However, a significant number of adolescent patients do not get better after completing cognitive behavioral therapy or experience relapse. Providing realistic learning contexts for exposure could be the key to enhancing treatment effects in adolescents. This is often challenging for a variety of reasons, including difficulty realistically mimicking anxiety-provoking social situations due to limited resources, clinician training, time, or motivation. Virtual reality environments could provide contextual exposures for social anxiety.
The aims of this study are threefold: to assess feasibility of using virtual reality in treatment of social anxiety in youth, to examine whether virtual reality invokes arousal similar to anxiety and test the physiological assessment protocol, and to evaluate whether exposure using virtual reality environments reduces symptoms of social anxiety and related functional impairment.
In our previous work, we have developed bio-markers from brain images of transcranial magnetic stimulation (TMS) treatment for depression.
The goal of the current study is to build on this past work by looking at the immediate neural effects of a single session of several forms of TMS, previously established to be effective and safe.
The findings of this study will help figure out the best TMS targets and forms of treatment in future intervention studies. Data from the current pilot trial will also inform future efforts to effectively match a TMS treatment method to each individual, based on this individual's brain patterns.
The purpose of this study is to compare two kinds of therapy for post-traumatic stress disorder (PTSD): exposure therapy (ET) and interpersonal psychotherapy (IPT). The results of this study will allow us to see if IPT and ET are equally effective in treating PTSD due to military sexual trauma, with the long-term goal of making PTSD treatment effective for as many people as possible.
We are seeking participants for a clinical trial which will test an experimental drug for the treatment of post-traumatic stress disorder (PTSD).
Following the initial screening phase, you will receive the medication treatment for 8 weeks and the placebo for 8 weeks. The study will last a total of 18 weeks, and you will be assessed at baseline and then every 2 weeks until the end of the study. You will be compensated for all completed assessments (up to a total of $400).
The purpose of this study is to treat symptoms of posttraumatic stress disorder (PTSD) resulting from burn trauma using traditional treatment.
The burn intervention study offers 14 sessions of free individual treatment for burn survivors with posttraumatic stress disorder. The treatment protocol focuses on reduction of the symptoms of PTSD, while simultaneously introducing skills to address the numerous sequelae of burn injury including feelings of depression, coping with scarring and/or disfigurement, reintegrating back into work, community, and social circles, and improving general functioning and quality of life.
We are conducting a randomized proof-of-concept study to assess the efficacy of virtual reality (VR) vs standard of care in 50 adult patients in the NewYork-Presbyterian Burn Unit. The participants who are randomized to receive the virtual reality intervention will also receive opioids, which is the standard of care and is known to be effective.
Participants will be randomly assigned to two groups. The first group will receive VR during their procedure in addition to the standard-of-care. The other group will receive standard of care during the wound dressing change procedure (and no VR). The reported levels of pain and the total amount of narcotic and analgesics from admission through discharge from the hospital will be recorded and analyzed as a secondary outcome: whether the VR condition impacts total received dose in the two days post-procedure and through hospital stay.
The purpose of this study is to treat symptoms of post-traumatic stress disorder (PTSD) resulting from various traumas using traditional treatment combined with the use of D-Cycloserine (DCS).
Treatment is offered on an individual basis for 12-14 weekly sessions lasting approximately 75-90 minutes each. This cognitive-behavioral treatment aims to introduce skills and techniques that will reduce symptoms and improve quality of life. One essential component of the treatment includes describing one's traumatic experience. Participants will be randomly assigned to take either a low dose of D-Cycloserine (DCS; a broad-spectrum antibiotic) or a placebo pill prior to their weekly session to examine the effects of DCS on treatment. Thus treatment incorporates traditional techniques that have been shown to be effective in treating PTSD, with cutting edge pharmacology to enhance the treatment. Treating clinicians are all highly experienced in working with PTSD, civilians and disaster workers.
Depression is the second leading cause of disability worldwide, due partly to the fact that existing antidepressants are not effective for all patients and it is often challenging to match individual patients to the treatments that are most likely to help them. This study will test a new strategy for using fMRI brain scans to predict antidepressant response and assist clinicians in choosing antidepressant treatments. Transcranial magnetic stimulation targeting one of two depression-related brain areas is most likely to benefit an individual patient.
The goal of this study is to learn about changes in the brain that occur during Engage, a psychotherapy for depression in older adults, and how they may differ from changes that occur during supportive therapy. Older adults with depression will receive 9 weeks of either Engage or supportive therapy and will complete research assessments before the therapy begins and at weeks 3, 6, and 9 of treatment. Research assessments will include questionnaires, computer tasks, and recordings of electrical brain activity (also called electroencephalography or EEG).
The purpose of this study is to compare thinking, emotions, and brain function in older adults without a history of psychiatric illness to older adults who are receiving treatment for depression in our other studies. This research is being done to help develop, understand, and improve treatments for depression in older adults.
Research assessments will be conducted at three time points – baseline, week 6, and week 9 – and will include measuring brain activity, computer tasks, and questionnaires about mood and thoughts. Participants are compensated for each visit.
The purpose of this clinical trial is to determine whether screening for breast cancer with tomosynthesis mammography is superior to digital mammography. To determine that, we are studying whether women who are screened for breast cancer with tomosynthesis mammography have fewer advanced breast cancers compared with the number of such cancers found when women are screened for breast cancer with digital mammography. This study will also compare whether there is a difference in the number of additional tests recommended after tomosynthesis mammography and digital mammography.
Weill Cornell Medical College researchers seek participants who experienced a traumatic event for a one year post traumatic stress disorder (PTSD) study. Participants will be assessed for PTSD and related symptomatology and followed up for 1 year. Participants will also contribute saliva sample for genetic biomarkers analysis.
This study aims to test genetic predictors of PTSD following trauma and to understand the longitudinal course of PTSD in trauma survivors, including psychiatric symptoms, impairment, and reaction to reintegration to daily life. All assessments are free of cost and confidential.
This clinical trial is for men and women diagnosed with metastatic pancreatic cancer as well as healthy individuals. The purpose of this research study is to develop a safe method for finding pancreatic cancer using a new technology of finding and detecting pancreatic cancer DNA markers in adult urine. In order to continue to improve the way pancreatic cancer is found in patients, the researchers must be able to obtain urine samples from patients who may or may not have pancreatic cancer and test their urine for DNA fragments that contains pancreatic DNA markers. Eligible patients will have urine and blood collected for correlative reference.
The Weill Cornell Institite of Geriatric Pyschiatry is conducting a research study of depression in adults ages 45-75 years old using a cognitive training delivered on iPads. This study is voluntary and will not influence your regular medical care. iPads are provided on loan.
Eligible individuals who agree to participate will:
Participants will not be charged for any services. Participants will be compensated up to $575 by the end of the study.
All information is confidential. To learn more, please call (646) 289-5204 ext. 701.
This study is for men and women who are 65 years or older with cancer and informal caregivers of people 65 years or older with cancer. Informal caregivers are family and/or friends of cancer patients who provide physical, emotional, and/or practical support to the patient and are not paid for providing this care.
To participate in this study, patients and/or caregivers must also be experiencing elevated anxiety levels. This study is being conducted because approximately 60% of new cancer diagnoses are in patents 65 years or older, anxiety is common in these patients and their caregivers, and psychological interventions specifically for older adults with cancer and their informal caregivers have not been developed and evaluated. The purpose of this study is to determine whether the intervention has a clinically significant effect on patients' and caregivers' anxiety.
The purpose of this study is to find out if participating in activities that train cognitive skills can improve your ability to manage your emotions.
This research study is being done because severe mental illnesses can contribute to problems managing emotions during stressful situations. These difficulties with managing emotions result from difficulties with cognition. Cognition refers to your thinking skills—your ability to remember, focus, think quickly, reason, solve problems, and recognize other people’s emotions. We are interested in finding out if by training your thinking skills; we can improve your ability to manage emotions and aggression.
We have developed a program that includes several activities that help people think better faster, and more efficiently. The purpose of the study is to see if the treatment program that includes computer training activities can help improve your thinking skills and your ability to manage your emotions.
Currently recruiting: People with lung disease and Healthy Volunteers
This clinical trial is designed to collect samples from healthy individuals and individuals with lung disorders to compare specific factors in each. Blood, urine, and airway cells are collected to learn more about the specific causes of lung disease, how lung disease manifests, progresses, and how it can be treated. Normal healthy volunteers will be used to establish what is considered a normal range for various parameters. This trial is also used to store specimens for future genetic studies.
The purpose of this study is to collect samples from healthy individuals and individuals with lung disease to help in the understanding of the origins and mechanisms of various lung disorders. The main idea is to see if there are changes within the genetic expression of airway cells in patients with lung disorders before there are actual physical changes within the lungs.
This is a collection study, and no study medication will be given to treat airway disorders. This study is comprised of three main parts. The first is a telephone pre-screening interview. The interview will take about 15 minutes, where questions will be asked about the subject’s background. This will determine if a subject is eligible for the second portion of the study, called the initial screening visit. This will take 4-5 hours and may include blood and urine tests, a physical exam, a chest x-ray, an EKG, and a breathing test. Compensation for completion of the initial screening visit will be $50. If a subject is considered eligible, they will undergo the third part of the study, called the bronchoscopy. A bronchoscopy is a routine procedure doctors use to look at the inside airways of the lungs. A very thin and flexible tube is inserted down the throat into the lungs for sample collection. The bronchoscopy will take about 2 hours.
Potential subject compensation as follows:
Full screening: $50
Partial screening: $25
Patient referral (if referred patient completed entire study): $25/patient
Weill Cornell Medicine psychiatrists are recognized research leaders who maintain the highest level of integrity and human subject protection. Clinical studies are currently underway to develop and test new medications and forms of psychotherapy as well as introduce new methods of imaging techniques to research science. Novel therapies, including the use of virtual reality technology, are also being examined for use as treatment. All clinical studies depend upon individuals participating in a variety of meaningful investigations.